⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCGN News
Ocugen, Inc. Common Stock
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
globenewswire.com
OCGN
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
globenewswire.com
OCGN
Form 8-K
sec.gov
OCGN
Form 8-K
sec.gov
OCGN
Form 8-K
sec.gov
OCGN
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
OCGN
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
prnewswire.com
NAGE
OCGN
NTLA
GERN
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
globenewswire.com
OCGN
ODIN SafeWave EMF Blocking Sticker Review 2026: Don't Buy Without Reading This First!
accessnewswire.com
OCGN
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
OCGN